Toshiyuki Tamai

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.

E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.

Journal: ESMO open

Published: July 09, 2025

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 08, 2023

Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles.

Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles.

Journal: Investigational new drugs

Published: May 06, 2022

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.

Journal: Expert review of anticancer therapy

Published: March 09, 2022

Impact of bodyweight-based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma.

Impact of bodyweight-based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 03, 2022

Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.

Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.

Journal: Liver cancer

Published: December 11, 2020

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.

Journal: Journal of gastroenterology

Published: November 20, 2020

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 13, 2020

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: August 28, 2020

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.

Journal: Journal of hepatology

Published: June 23, 2020

Comparison of efficacy outcomes of anticancer drugs between Japanese patients and the overall population.

Comparison of efficacy outcomes of anticancer drugs between Japanese patients and the overall population.

Journal: International journal of clinical oncology

Published: May 19, 2020

REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.

REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.

Journal: Journal of gastroenterology

Published: April 12, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026